Gene-based Revolution in Cholesterol Treatment on the Brink of Breakthrough!?
Verve's one-time gene-editing therapy for high cholesterol could completely revolutionize the existing standard treatment with an efficacy of up to 69%!
Reading Time: 1 minute
I am optimistic about the recent clinical successes at Verve Therapeutics! The Phase 1b results of their gene-editing therapy VERVE-102 show very positive progress. An average LDL cholesterol reduction of 53% with a single infusion is groundbreaking for patients with familial hypercholesterolemia. What particularly encourages me is that the treatment was very well tolerated, with no serious side effects. The FDA designation as "Fast Track" underscores the transformative potential of this therapy. With the planned Phase 2 study at the end of the...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
